Key Points
- Director Faith Charles bought 7,100 shares of CNS Pharmaceuticals at $4.79 each, a transaction worth about $34,009, according to an SEC filing.
- The stock opened at $5.10 and the company remains very small, with a $4.13 million market cap and a highly volatile beta of 2.62.
- CNS Pharmaceuticals recently reported a quarterly EPS loss of $7.30, which was better than the expected loss of $8.82, while analysts currently rate the stock Hold on average with a $20 target price.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP - Get Free Report) Director Faith Charles acquired 7,100 shares of the stock in a transaction dated Monday, May 18th. The shares were purchased at an average price of $4.79 per share, for a total transaction of $34,009.00. Following the completion of the purchase, the director directly owned 7,100 shares in the company, valued at $34,009. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
CNS Pharmaceuticals Price Performance
CNS Pharmaceuticals stock opened at $5.10 on Thursday. The firm has a market capitalization of $4.13 million, a PE ratio of -0.17 and a beta of 2.62. The company's 50-day moving average is $3.29 and its 200-day moving average is $4.84. CNS Pharmaceuticals, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $15.73.
CNS Pharmaceuticals (NASDAQ:CNSP - Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($7.30) EPS for the quarter, topping the consensus estimate of ($8.82) by $1.52.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Boothbay Fund Management LLC acquired a new position in CNS Pharmaceuticals in the 4th quarter valued at about $71,000. Ikarian Capital LLC acquired a new position in CNS Pharmaceuticals in the 4th quarter valued at about $241,000. Finally, Armistice Capital LLC acquired a new position in CNS Pharmaceuticals in the 2nd quarter valued at about $335,000. Institutional investors and hedge funds own 14.02% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of CNS Pharmaceuticals in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $20.00.
Get Our Latest Report on CNS Pharmaceuticals
CNS Pharmaceuticals Company Profile
(
Get Free Report)
CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company's lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.
Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
